Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED AND NOTICE OF EGM

06/22/2021 | 05:11am EDT

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agents through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED

AND

NOTICE OF EGM

A letter from the Board is set out on pages 3 to 5 of this circular. The notice convening the EGM of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* to be held at 1:30 p.m. on Wednesday, 14 July 2021 at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC is set out on pages EGM-1 to EGM-2 of this circular. A form of proxy for use at the EGM is enclosed herewith and also published on the websites of the Hong Kong Stock Exchange (http://www.hkexnews.hk) and of the Company (http:// www.fosunpharma.com).

Whether or not you are able to attend the said meeting, you are reminded to complete, sign and return the form of proxy enclosed, in accordance with the instructions printed thereon. The form of proxy shall be lodged at the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 24 hours before the holding of the EGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM should you so wish.

  • for identification purposes only

23 June 2021

CONTENTS

Page

Definitions .

. . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

Letter from the Board . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

Appendix

-

Report on the Use of Proceeds Previously Raised . . . . . . . . . . . . . . . . . .

I-1

Notice of EGM . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EGM-1

- i -

DEFINITIONS

Unless the context otherwise requires, the following expressions in this circular shall have the following meanings:

''A Share(s)''

domestic share(s) with a nominal value of RMB1.00 each in

the share capital of the Company, which is (are) listed on the

Shanghai Stock Exchange and traded in RMB

''Board''

the board of directors of the Company

''Company''

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星

醫藥(集團)股份有限公司), a joint stock company established

in the PRC with limited liability, the H Shares and A Shares of

which are listed and traded on the main board of the Hong

Kong Stock Exchange and the Shanghai Stock Exchange,

respectively

''CSRC''

China Securities Regulatory Commission (中國證券監督管理

委員會)

''Director(s)''

the director(s) of the Company

''EGM''

the 2021 second extraordinary general meeting of the

Company to be held at 1:30 p.m. on Wednesday, 14 July

2021 at Shanghai Film Art Center, No. 160 Xinhua Road,

Shanghai, the PRC (or any adjournment thereof)

''Group''

the Company and its subsidiaries

''H Shares''

overseas listed foreign share(s) in the ordinary share capital of

the Company, with a nominal value of RMB1.00 each, which

are listed on the Hong Kong Stock Exchange and traded in

Hong Kong dollars

''Hong Kong''

the Hong Kong Special Administrative Region of China

''Hong Kong Listing Rules''

the Rules Governing the Listing of Securities on The Stock

Exchange of Hong Kong Limited

''Hong Kong Stock Exchange''

The Stock Exchange of Hong Kong Limited

- 1 -

DEFINITIONS

''Proposed Non-public Issuance''

the proposed non-public issuance of no more than 5% of the

total number of the Shares prior to the Proposed Non-public

Issuance (i.e. no more than 128,144,927 A Shares (inclusive)

calculated on the basis of the total number of the Shares as at

the date of the first Board resolution approving the Proposed

Non-public Issuance) to no more than 35 particular investors

by the Company, which was approved by the Shareholders at

the general meeting of the Company held on 29 December

2020. Further details please refer to the circular of the

Company dated 8 December 2020

''PRC'' or ''China''

the People's Republic of China, for the purpose of this

circular, excluding Hong Kong, the Macau Special

Administrative Region and Taiwan region

''Report on the Use of Proceeds

Report on the Use of Proceeds Previously Raised as at 31

Previously Raised''

December 2020 of Shanghai Fosun Pharmaceutical (Group)

Co., Ltd.* ( 上海復星醫藥(集團)股份有限公司截至202012

31日前次募集資金使用情況報告》)

''RMB''

''Shareholder(s)''

''Share(s)''

''subsidiary(ies)''

Renminbi, the lawful currency of the PRC

holder(s) of Share(s)

share(s) of the Company, including H Shares and A Shares

has the meaning ascribed to it under the Hong Kong Listing Rules

''%''

per cent

- 2 -

LETTER FROM THE BOARD

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

Executive Director:

Registered Office:

Mr. WU Yifang (Chairman and CEO)

9th Floor, No. 510

Caoyang Road

Non-executive Directors:

Putuo District

Mr. CHEN Qiyu

Shanghai, 200063, China

Mr. YAO Fang

Mr. XU Xiaoliang

Headquarters:

Mr. GONG Ping

Building A

Mr. PAN Donghui

No. 1289 Yishan Road

Mr. ZHANG Houlin

Shanghai, 200233, China

Independent Non-executive Directors:

Principal Place of Business

Ms. LI Ling

in Hong Kong:

Mr. TANG Guliang

Level 54

Mr. WANG Quandi

Hopewell Centre

Mr. YU Tze Shan Hailson

183 Queen's Road East

Hong Kong

23 June 2021

To the Shareholders

Dear Sir or Madam,

REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED

AND

NOTICE OF EGM

  1. INTRODUCTION

The purpose of this circular is to give you notice of the EGM enclosed herewith, and to provide you with information regarding resolution to be proposed at the EGM regarding the Report on the Use of Proceeds Previously Raised to enable you to make informed decisions on whether to vote for or against the proposed resolution at the EGM.

- 3 -

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 09:10:04 UTC.


© Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,2x
Yield 2021 0,63%
Capitalization 165 B 25 482 M 25 485 M
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 81,88 CNY
Average target price 57,08 CNY
Spread / Average Target -30,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman